Sex differences in the development of prolactinoma in mice overexpressing hCG β : role of TGF β 1

Erika Y Faraoni¹, María Andrea Camilletti¹, Alejandra Abeledo-Machado¹,
Laura D Ratner¹, Fernanda De Fino², Ilpo Huhtaniemi³, Susana B Rulli¹
and Graciela Díaz-Torga¹

¹Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina

²Instituto de Investigaciones Farmacológicas, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina

³Department of Surgery & Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, London, UK

Correspondence
should be addressed
to G Díaz-Torga

Email
gdiaz@ibyme.conicet.gov.ar

Abstract

Female transgenic mice that overexpress the human chorionic gonadotrophin β subunit (hCG β +) develop prolactinomas, whereas hCG β + males do not. The high levels of circulating hCG induce massive luteinization in the ovary of hCG β + females, and progesterone becomes the primary steroid hormone produced, but estradiol remains at physiological level. The involvement of high levels of progesterone in lactotroph proliferation is not clearly understood; hence, the pathogenesis of prolactinomas in hCG β + females remains unclear. TGF β 1 is an inhibitor of lactotroph function, and the reduced TGF β 1 activity found in prolactinomas has been proposed to be involved in tumor development. The aim of the present work was to study the role of TGF β 1 in the gender-specific development of prolactinomas in hCG β + mice. We compared the expression of different components of the pituitary TGF β 1 system in males and females in this model. We found reduced TGF β 1 levels, reduced expression of TGF β 1 target genes, TGF β 1 receptors, *Ltbp1*, *Smad4* and *Smad7* in hCG β + female pituitaries. However, no differences were found between the transgenic and wild-type male pituitaries. We postulate that decreased pituitary TGF β 1 activity in hCG β + females is involved in the development of prolactinomas. In fact, we demonstrated that an in vivo treatment carried out for increasing pituitary TGF β 1 activity, was successful in reducing the prolactinoma development, and the hyperprolactinemia in hCG β + females. Moreover, the stronger TGF β 1 system found in males could protect them from excessive lactotroph proliferation. Sex differences in the regulation of the pituitary TGF β 1 system could explain gender differences in the incidence of prolactinoma.

Key Words

- ▶ pituitary
- ▶ prolactinoma
- ▶ hCG β
- ▶ TGF β 1

Journal of Endocrinology
(2017) **232**, 535–546

Introduction

The human chorionic gonadotrophin (hCG), secreted normally by the placenta, is a member of the family of glycoprotein hormones (with the pituitary hormones LH, FSH and TSH) that share structural similarities. They are heterodimers of two non-covalently associated subunits: the common α - and the hormone-specific β -subunit. Individually, each subunit has not known biological activity (Gharib *et al.* 1990).

The hCG β and the LH β subunits have 83% homology, but hCG β contains four additional O-linked glycosylation sites in a C-terminal extension of 24 amino acids, that confers to hCG β a longer circulatory half-life and higher biopotency as compared to LH (Gharib *et al.* 1990). Both LH and hCG interact with the same LH/hCG receptor, which belongs to the large family of G-protein-coupled receptors, promoting ovarian steroidogenesis and ovulation in females and testicular androgen production in males.

Elevated gonadotrophin secretion can be observed in female or male infertility and upon ovarian tumorigenesis. Genetically modified mouse models have provided fundamental tools to study disorders arising from the loss- or the gain-of-function of gonadotrophins in reproductive pathologies (reviewed in Jonas *et al.* 2014).

Phenotypes of the transgenic mouse model overexpressing the hCG β subunit (hCG β + mice) present gender differences. Although hCG β + males are fertile, with normal spermatogenesis and sperm quality despite reduced testis size and serum FSH (Rulli *et al.* 2003), females present precocious puberty, infertility, enhanced ovarian steroidogenesis and abnormal uterine structure (Rulli *et al.* 2002). Adult females develop mammary tumors with characteristics of adenocarcinoma at the age of 9–10 months. On the other hand, females, but not males, also develop prolactinomas. The pituitary enlargement becomes evident from the age of 2 months, and progress to adenoma by the age of 8–10 months, concomitant with severe hyperprolactinemia (Rulli *et al.* 2002).

Factors that trigger the prolactinoma development in hCG β + females are not fully elucidated. One of the most studied stimuli involved in prolactinoma development is the circulating estradiol level. In hCG β + females, the stimulation of the immature ovary by hCG induces transient high levels of estradiol with a 3- to 4-fold increase at one month of age. However, thereafter, the continuous high levels of circulating hCG induce massive luteinization, and progesterone becomes the predominant steroid hormone produced. Adult hCG β + female mice present with a 50- to 100-fold excess of progesterone,

3- to 6-fold-increase in testosterone but, interestingly, physiological levels of estradiol (Rulli *et al.* 2002). As the involvement of high levels of progesterone or testosterone in lactotroph proliferation is not clearly understood, new investigations are needed to clarify the pathogenesis of prolactinomas in hCG β + female mice.

The main regulators of lactotroph functions are dopamine (DA) and estradiol. They interact in the regulation of cell proliferation and prolactin (PRL) secretion (Maurer 1982, Ben Jonathan & Hnasko 2001). DA inhibits lactotroph proliferation and PRL synthesis and release, acting through the dopamine D2 receptor (Drd2) expressed in lactotrophs (Ben-Jonathan 1985, Missale *et al.* 1998). Estradiol stimulates PRL gene transcription modifying lactotrophic responses to other stimulatory or inhibitory factors and indirectly decreases DA production from the hypothalamus (Freeman *et al.* 2000). In addition, other hypothalamic or pituitary factors contribute to the regulation of lactotroph function (reviewed in Freeman *et al.* 2000). Among them, the locally produced transforming growth factor beta 1 (TGF β 1) is known for inhibiting lactotroph proliferation and PRL secretion (Sarkar *et al.* 1992, 1998, Recouvreur *et al.* 2011).

The TGF β biology is complex, and its activity is highly regulated due to its powerful effects on embryogenesis, development and tissue homeostasis (Heldin *et al.* 2009, Galvin-Burgess *et al.* 2013, Itoh *et al.* 2014).

In the pituitary, DA and estradiol, the main regulators of lactotroph function, regulate TGF β 1 synthesis and activation, and the expression of several components of the TGF β 1 system (Recouvreur *et al.* 2011, 2013). DA increases the TGF β 1 expression in lactotrophs (Sarkar *et al.* 2005), whereas estradiol decreases cytokine synthesis and release and type 2 TGF β receptor (T β R2) expression (Sarkar *et al.* 1992, Pastorcic *et al.* 1995). Moreover, it was previously demonstrated that TGF β 1 mediates, at least in part, the DA and estradiol effect on lactotroph functions.

The importance of TGF β 1 in inhibiting lactotroph function is clearly demonstrated by the fact that in human prolactinomas, as well as in animal models of prolactinomas, the TGF β 1 expression and activity were found reduced, suggesting its involvement in the tumor development (Pastorcic *et al.* 1995, Recouvreur *et al.* 2011, 2012, 2016).

The aim of the present work was to study the involvement of TGF β 1 system in the development of prolactinoma in hCG β + mice, and in the gender differences observed in the appearance of this phenotype.

Materials and methods

Animals

All studies were performed in transgenic mice from both sexes, overexpressing the hCGβ subunit under the control of human ubiquitin C promoter (hCGβ+). In all cases, wild-type (WT) littermates were used as controls. These mice, with FVB/N background, were genotyped as previously described (Rulli *et al.* 2002). Animals were kept in a temperature-controlled room with lights on at 07:00h and off at 19:00h and were given free access to laboratory chow and tap water.

All experimental procedures were performed according to the NIH Guidelines for Care and Use of Experimental Animals (Division of Animal Welfare, Office for Protection of Research Risks, National Institutes of Health, A#5072-01) and were approved by the Institutional Animal Care and Use Committee of the Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas (IBYME-CONICET).

Animals were used at 6 months of age, at which age the pituitaries from hCGβ+ females were hyperplastic. Trunk blood was collected after decapitation, and anterior pituitaries were weighed after removal. Serum samples were separated by centrifugation and stored at −20°C for biochemical analyses. Anterior pituitaries of different experimental groups were stored in TRIzol (Invitrogen) or ice-cold buffer containing a mix of proteases inhibitors at −70°C for posterior RNA isolation and ELISA assays, respectively.

Radioimmunoassay (RIA)

Serum prolactin levels were measured by RIA using mouse-specific reagents provided by the National Institute of

Diabetes and Digestive and Kidney Diseases and National Hormone and Pituitary Program (Dr A F Parlow, NHPP, Torrance, CA). Assays were performed using 10μL serum in duplicate. Results are expressed in nanograms per milliliter. The inter- and intra-assay coefficients of variation were 6.9% and 11.6%, respectively.

RNA isolation and analysis of gene expression

Anterior pituitaries and hypothalami were collected and processed in TRIzol Reagent (Invitrogen), and total RNA was isolated according to manufacturer's protocol. One microgram of RNA was reverse-transcribed in a 20μL reaction volume using MMLV-RT (Promega) and random primers (Biodynamics). The resulting cDNA was used for quantitative real-time PCR analysis (qPCR). qPCRs were performed using specific-designed primers and the Fast Start Universal SYBR Green Master Rox (Roche) on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Differences in the cDNA target gene expression were quantified by comparing the threshold cycle (CT) with that of *CyclophilinB* using the comparative CT method (ΔΔCT). The primer sequences used for qPCR are shown in Table 1.

Detection of total and active TGFβ1

ELISAs were performed to quantify total or active TGFβ1 concentration in pituitary homogenates using the TGFβ1 DuoSet ELISA development system (DY1679, R&D Systems), following the manufacturer's instructions.

Anterior pituitaries of different groups were collected and homogenized in 100μL of ice-cold buffer containing 100mM Tris, 10mM CaCl₂, 1mM MgCl₂, 1% Triton X-100, pH 7.4 and a mix of proteases inhibitors

Table 1 Primer sequences for qPCR.

Gene	Forward primer 5'–3'	Reverse primer 5'–3'
<i>CyclophilinB</i>	GACCCTCCGTGGCCAACGAT	ACGACTCGTCCTACAGATTCATCTC
<i>TβR2</i>	AATCCCAGCTTCTGGCTCA	GTGCTGTGAGAGACGCGGGCTTC
<i>Tmeip1</i>	TGTCCTCGGAAGGATGCCTCTGG	CAGCGAGTCGGTCAGTGGGC
<i>Klf14</i>	CAGCTCGTCTGGCTCCAA	AGGCACTCGGCAGCGAA
<i>Alk5</i>	TCCAAACCACAGAGTAGGCAC	TCATGGATTCCACCAATAGAACA
<i>Alk1</i>	GCGTTGACCAGCAGACACCC	CAGTGCGGTGAGGCGAGCAG
<i>Smad4</i>	CACCCGCCAAGTAATCGCGCA	CTGGCCGGCTGACTTGTGGAAG
<i>Smad7</i>	AACCCGAGCTGGTGTGCTG	TGGACAGCCTGCAGTTGGTTGA
<i>Ltbp1</i>	AGCACCATCACCTCTGCTCT	CAGACACTGCTGCTCCAA
<i>Th</i>	CCAGAGAGGACAAGGTTCCC	ATACGCCTGGTCAGAGAAGC
<i>Drd2</i>	ATCGTCTCGTTCTACGTGCC	GTTGCCCTTGAGTGGTGTC
<i>Tgfb3</i>	TGAGCTCTCCAGATACTTCGAC	GGATGCTGATTTCCAGACCCA
<i>Bmp4</i>	TTGCAGCTTCTAGAGGTCCC	TCAGCATTCCGTTACCAGGAA

(phenylmethylsulfonyl fluoride, tosyl phenylalanyl chloromethyl ketone, tert-Amyl methyl ether, N-carbobenzyloxy-L-phenylalanine chloromethyl ketone and tosyl-L-lysyl chloromethyl ketone), using a hand-held micro-tissue homogenizer. The homogenates were centrifuged at 8900g for 10 min at 4°C. The supernatant was collected, and protein concentration was measured by Lowry method. Equal protein amounts were loaded per well. TGF β 1 concentration was expressed as picograms per milligrams of protein. To assay total TGF β 1, samples were previously acidified to pH 2.6 by adding 1 M HCl for 20 min at room temperature, followed by neutralization with 1 M NaOH to pH 7.6.

Determination of DA concentration in hypothalamic tissue by HPLC

Whole hypothalami, including the preoptic area, were excised considering an area limited anteriorly by the optic chiasma and laterally by the hypothalamic fissures. The posterior limit was a plane passing in the limit with the mammillary bodies, excluding them. The in-depth limit was the subthalamic sulcus. Tissues were kept at -70°C until used.

HPLC-coupled electrochemical detection of DA was performed using a Varian 5000 liquid chromatograph coupled to an electrochemical detector (BAS LC-4C). Hypothalamic tissues were weighed, homogenized and deproteinized in 0.2 N perchloric acid (1/20). Homogenates were centrifuged. The supernatants were injected (50 μ L) onto a 12.5 cm $\times$ 4 mm Nova-Pak C18 (Waters) reverse phase column. Mobile phase for DA determinations contained NaH₂PO₄·H₂O 0.076 M, EDTA 0.99 mM, PICB8 5.24 mL/L and 6% methanol. The electrode potential was fixed at 0.7 V. Peak heights were measured by Peak Simple Chromatography Data System (Model 302 Six Channel USB). Values were quantified based on standard curves using the same software. DA concentration was determined based on tissue wet weight.

Experimental protocol for ABT-898 treatment

Four-month-old hCG β + female mice were divided into two groups and treated with 100 mg/kg ABT-898 (i.p.) or vehicle (5% dextrose, control group). The drugs were injected three times per week during three weeks. Twenty-four hours after the last injection, animals were killed, and trunk blood was collected for serum PRL determination by RIA. Pituitaries were carefully excised and weighed after removing the neurohypophysis. Anterior pituitaries

were used for TGF β 1 ELISA assay and for pituitary PRL concentration measurement by RIA. Female WT siblings were used as control.

Drug ABT-898 peptide was generously supplied by Abbott Laboratories.

Statistical analysis

Results are expressed as mean $\pm$ S.E.M. Two-way ANOVA was performed, as the effects of two factors (genotype and gender) were evaluated, followed by Bonferroni's *post hoc* test. Dopamine concentration measurements were evaluated by Student's *t* test. The *in vivo* treatment results were evaluated by one-way ANOVA followed by Tukey's honestly significant difference test. *P* < 0.05 was considered significant. Data were transformed when required.

Results

Sex differences in pituitary weight and prolactin secretion in WT and hCG β + mice

As it was previously shown (Rulli *et al.* 2002, Ahtiainen *et al.* 2010, Ratner *et al.* 2012), hCG β + female mice developed prolactinomas, presenting a markedly increase in pituitary weight compared to their WT counterparts at 6 months of age (Fig. 1A, *P* < 0.0001). Nevertheless, no differences among genotypes were found in the pituitary weight in males, instead of both sexes hCG β + mice presenting with elevated levels of bioactive

Figure 1

Sex differences in pituitary weight and prolactin secretion in WT and hCG β + mice. (A) Pituitary weight (mg) of 6-month-old mice (*n* = 11–12/group). Two-way ANOVA: genotype $\times$ sex interaction (*P* = 0.0002). Bonferroni's *post hoc* test: Differences among genotypes were observed only in females (**P* < 0.0001 vs wt female). (B) Serum prolactin levels were measured by RIA (*n* = 11–12/group). Genotype $\times$ sex interaction (*P* < 0.0001). Significant differences among genotypes were observed only in females (**P* < 0.0001 vs wt female).

LH/hCG (males 21 ± 4 , females 99 ± 20 IU/L; Rulli *et al.* 2002, 2003).

In correlation to the pituitary weight, serum prolactin levels were also found significantly increased in hCG β + female mice compared to their WT counterparts (Fig. 1B, $P < 0.0001$), whereas no differences were found among genotypes in males.

Sex differences in active and total TGF β 1 concentration in pituitaries from WT and hCG β + mice

We next evaluated whether sex differences found in pituitary weight and prolactin secretion from hCG β + mice could be related to alterations in the local TGF β 1 system.

When we measured pituitary TGF β 1 concentration by ELISA, we found higher levels of both total and active TGF β 1 in male pituitaries compared to female mice (Fig. 2A, $P < 0.0001$; Fig. 2B, $P < 0.0001$). A lower concentration of both total (Fig. 2A, $P < 0.001$) and active (Fig. 2B, $P < 0.01$) TGF β 1 was found in hCG β + female mice when compared to their WT siblings. On the other hand, no differences among genotypes were found in cytokine content in pituitaries from males.

TGF β 1 biological activity

To evaluate whether the lower levels of active TGF β 1 found in pituitaries from hCG β + female mice affect the biological activity of the cytokine, we measured the expression of two known TGF β 1 target genes: the Krüppel-like factor 14 (*Klf14*) (Truty *et al.* 2009) and the transmembrane androgen-induced protein (*Tmepai*) (Brunschwig *et al.* 2003, Levy & Hill 2005). *Klf14* and *Tmepai* mRNA expression were found higher in male mice compared to that in females (Fig. 3A and B, respectively, $P < 0.0001$), according to the sex differences observed in pituitary-active TGF β 1 content. Both *Klf14* and *Tmepai* mRNA expression were found decreased in female hCG β + compared to their WT counterparts (Fig. 3A and B, $P < 0.001$). This finding is in agreement with the marked decrease in total and active TGF β 1 content observed in hCG β + female pituitaries (Fig. 2).

TGF β 1 receptors

The expression of the type 1 (*Alk1* and *Alk5*) and type 2 (*Tbr2*) TGF β receptors was found increased in male pituitaries compared to that in females (Fig. 4, $P < 0.0001$). No genotype differences were found in males, but in

Figure 2

Active and total TGF β 1 concentration in pituitaries from WT and hCG β + mice. Active and total TGF β 1 content was measured by ELISA in pituitary homogenates ($n = 8-9$ /group). (A) Total TGF β 1: Two-way ANOVA, genotype $\times$ sex interaction ($P = 0.0054$). Bonferroni's *post hoc* test was conducted as the interaction between effects was significant. Differences among gender: a, $P < 0.0001$. Differences among genotypes were observed only in females ($*P < 0.001$ vs wt female). (B) Active TGF β 1 concentration: Two-way ANOVA, genotype $\times$ sex interaction ($P = 0.0274$). Bonferroni's *post hoc* test: Sex differences: a, $P < 0.0001$. Significant differences among genotypes were observed only in females ($*P < 0.01$).

females, the mRNA expression of *Tbr2* (Fig. 4A, $P < 0.001$) and *Alk5* (Fig. 4B, $P < 0.001$) was found reduced in hCG β + compared to their WT counterparts. On the other hand, no differences among genotypes were found in *Alk1* expression in female pituitaries (Fig. 4C).

Other components of TGF β 1 system

When we measured the mRNA expression of *Smad4* and *Smad7*, we also observed gender and sex differences. Both

Figure 3

Sex and genotype differences in TGF β 1 biological activity. mRNA transcripts were amplified with specific primers by qPCR and normalized to *CyclophilinB*. Results are expressed relative to those for WT females ($n = 7-11$ /group) and analyzed by two-way ANOVA. Bonferroni's *post hoc* test was conducted as the interaction between effects was significant. (A) *Klf14* mRNA expression: genotype $\times$ sex interaction ($P = 0.0036$). Sex differences: a, $P < 0.0001$. Differences among genotypes were observed only in females ($*P < 0.001$ vs wt female). (B) *Tmepai* mRNA expression. Genotype $\times$ sex interaction: $P = 0.0003$. Sex differences: a, $P < 0.0001$. Differences among genotypes were observed only in females ($*P < 0.001$ vs wt females).

Figure 4

Sex differences in TGF β 1 receptors expression. mRNA transcripts were amplified with specific primers by qPCR and normalized to *CyclophilinB*. Results are expressed relative to those WT females ($n=7-12$ /group) and analyzed by two-way ANOVA. Bonferroni's *post hoc* test was conducted as the interaction between effects was significant. (A) *TβR2* mRNA expression: genotype $\times$ sex interaction ($P=0.0003$). Sex differences: a, $P<0.0001$. Differences among genotypes were observed only in females ($*P<0.001$ vs wt female). (B) *Alk5* mRNA expression: genotype $\times$ sex interaction $P=0.0004$. Sex differences: a, $P<0.0001$. Differences among genotypes were observed only in females ($*P<0.001$ vs wt female). (C) *Alk1* mRNA expression. Genotype $\times$ sex interaction was no significant. Sex differences: a, $P<0.0001$.

Smads presented higher expression in male pituitaries compared to females ($P<0.05$), but without differences among genotypes. On the other hand, *Smad4* and *Smad7* mRNA expression were found decreased in pituitaries from female hCG β + compared to their WT counterparts (*Smad4* Fig. 5A; *Smad7* Fig. 5B; $P<0.001$).

On the other hand, latent TGF β -binding protein 1 (*Ltbp1*) expression was also found increased in male pituitaries when compared to females (Fig. 5C, $P<0.0001$). Reduced *Ltbp1* expression was found in hCG β + female pituitaries compared to their WT counterparts ($P<0.01$), whereas no differences among genotypes were found in males.

Dopaminergic system

As it was demonstrated that DA increases TGF β 1 expression in lactotrophs (Sarkar *et al.* 2005), as well as the pituitary TGF β 1 activity (Recouvreux *et al.* 2011),

we were interested in evaluating whether a decreased dopaminergic tone could be involved in the decreased pituitary TGF β 1 activity. For this purpose, we measured the tyrosine hydroxylase (TH) expression in hypothalamic homogenates. We found decreased *Th* mRNA in males compared to females (Fig. 6A, $P<0.0001$), but without genotype differences. On the other hand, *Th* expression was found reduced in hCG β + females compared to their WT siblings ($P<0.001$). This result could imply a lower dopaminergic tone reaching the pituitary in this group. We next measured the pituitary expression of *Drd2* in all groups. As shown in Fig. 6B, the *Drd2* expression was found higher in male pituitaries compared to females, in accordance with lower dopaminergic tone in this sex ($P<0.0001$), without differences among genotypes. But in females, the *Drd2* expression was found significantly increased in hCG β + group compared to their WT siblings ($P<0.001$), as expected when the dopaminergic tone is reduced. Finally, to know whether genotype differences

Figure 5

Sex and genotype differences in other components of TGF β 1 system. mRNA transcripts were amplified with specific primers by qPCR and normalized to *CyclophilinB*. Results are expressed relative to those WT females ($n=5-12$ /group) and analyzed by two-way ANOVA. Bonferroni's *post hoc* test was conducted when the interaction between effects was significant. (A) *Smad4* mRNA expression: genotype $\times$ sex interaction ($P=0.0027$). Sex differences: a, $P<0.0001$. Differences among genotypes were found only in females ($*P<0.05$ vs wt female). (B) *Smad7* mRNA expression. Genotype $\times$ sex interaction: $P=0.0137$. Sex differences: a, $P<0.0001$. Differences among genotypes were found only in females ($*P<0.001$ vs wt female). (C) *Ltbp1* mRNA expression: genotype $\times$ sex interaction ($P=0.01$). Sex differences: a, $P<0.0001$. Differences among genotypes were found only in females ($*P<0.01$ vs wt female).

Figure 6

Sex and genotype differences in dopaminergic system. (A and B) mRNA transcripts were amplified with specific primers by qPCR and normalized to *CyclophilinB*. Results are expressed relative to those WT females ($n=5-7$ /group) and analyzed by two-way ANOVA. Bonferroni's *post hoc* test was conducted when the interaction between effects was significant. (A) *Th* mRNA expression: genotype $\times$ sex interaction ($P=0.0021$). Sex differences: a, $P<0.0001$. Differences among genotypes were found only in females ($*P<0.001$ vs wt female). (B) Dopamine D2 receptor gene (*Drd2*) mRNA expression. Genotype $\times$ sex interaction ($P=0.0021$). Sex differences: a, $P<0.0001$. Differences among genotypes were found only in females ($*P<0.001$ vs wt female). (C) DA concentration in female hypothalami performed by HPLC. Results are expressed relative to WT females ($n=6$ /group). Student's *t* test was performed ($P=0.6334$), no differences were found between groups.

found in hypothalamic *Th* expression in females were reflected in DA concentration, we evaluated the hypothalamic DA concentration by HPLC in WT and hCG β + females. As it could be observed in Fig. 6C, we did not find differences among groups.

Thrombospondin 1 (TSP-1) synthetic analogue ABT-898 normalizes pituitary-active TGF β 1 levels in hCG β + females

TSP-1 is a large multifunctional glycoprotein, component of the extracellular matrix, involved in multiple biological processes such as angiogenesis, apoptosis and activation of TGF β 1 (Lawler 2002). ABT-898 (Abbott Laboratories) is a TSP-1 synthetic analogue that mimics TSP-1 antiangiogenic action (Haviv *et al.* 2005). We have previously studied the effect of ABT-898 on experimental prolactinomas induced by chronic diethylstilbestrol (DES) treatment in female rats (Recouvreux *et al.* 2012). We demonstrated that an *in vivo* ABT-898 treatment markedly enhanced pituitary-active TGF β 1 concentration in the tumors, counteracted the increase in pituitary size and reduced the serum prolactin levels, as well as pituitary proliferation rate induced by DES.

To demonstrate the involvement of the reduced pituitary TGF β 1 activity in prolactinoma development in hCG β + female mice, we next conducted the ABT- *in vivo* treatment in our experimental model. We found that ABT-898 treatment in fact recovered the pituitary-active TGF β 1 concentration (Fig. 7A). In accordance, pituitary weight was reduced in the ABT-treated hCG β + group (Fig. 7B, $P<0.05$), as well as the serum prolactin levels (Fig. 7C, $P<0.01$). As females used in this experiment were younger

(4–5 months) than the previously used mice (Fig. 1B, 6–7 months), the hyperprolactinemia observed in hCG β + females was not as high as previously observed, since serum PRL levels increase exponentially from 3 months onwards. On the other hand, Fig. 7D shows higher PRL concentration in WT pituitary homogenates, due to the normal inhibitory effect of dopamine and TGF β 1 on hormone secretion. But the pituitary PRL concentration decreased in prolactinomas from hCG β + control female because this inhibition was lost ($P<0.001$). Interestingly, as ABT treatment enhanced biological TGF β 1 activity, the inhibition on hormone secretion was recovered ($P<0.05$).

Other members of TGF β family

Finally, as other members of the TGF β growth factor family, such as TGF β 3 and BMP4, have also been involved in prolactinoma development, we next measured the mRNA expression of these factors in our experimental model. As Fig. 8A shows, we did not find genotype differences in pituitary *Tgfb3* mRNA levels in females. However, we found a gender difference: decreased *Tgfb3* mRNA levels were found in male pituitaries related to females ($P=0.0009$).

On the other hand, when we evaluated pituitary *Bmp4* mRNA levels, it was found significantly reduced in hCG β + female pituitaries compared to WT littermates (Fig. 8B, $P<0.001$). Interestingly, we found an important gender difference in pituitary *Bmp4* expression: *Bmp4* levels were significantly reduced in male pituitaries compared to females ($P<0.0001$).

These results show that neither BMP4 nor TGF β 3 are involved in prolactinoma development in hCG β + females.

Figure 7

Thrombospondin 1 (TSP-1) synthetic analog ABT-898 normalizes pituitary active TGF- β 1 level. (A) Active TGF β 1 concentration was measured by ELISA in pituitary homogenates ($n=5-7/\text{group}$). One-way ANOVA followed by Tukey's test was performed ($P=0.0007$). hCG β + control pituitaries showed lower active cytokine concentration levels compared to WT females ($*P<0.05$). ABT treatment increased active TGF β 1 levels in hCG β + pituitaries (ABT-898) compared to control hCG β + females ($***P<0.001$). (B) Pituitary weight (mg, $n=5-7/\text{group}$). One-way ANOVA was performed followed by Tukey's test ($P=0.0054$). hCG β + control females showed higher pituitary weight compared to WT ($**P<0.01$). hCG β + ABT-898-treated female mice showed decreased pituitary weight compared to hCG β + control group ($*P<0.05$). (C) Serum prolactin levels measured by RIA ($n=5-7/\text{group}$). One-way ANOVA was performed followed by Tukey's test ($P<0.0001$). hCG β + control females showed higher serum PRL levels compared to WT ($***P<0.001$). hCG β + ABT-898-treated female hCG β + mice showed decreased serum PRL levels compared to hCG β + control female group ($**P<0.01$). (D) Pituitary PRL concentration measured by RIA in pituitary homogenates ($n=5-7/\text{group}$). One-way ANOVA was performed followed by Tukey's test ($P=0.0004$). hCG β + control females as well as hCG β + ABT-898-treated females showed lower pituitary PRL concentration levels compared to WT ($***P<0.001$). However, hCG β + ABT-898-treated group partially recover pituitary PRL content, showing increased pituitary PRL concentration levels compared to hCG β + control group ($*P<0.05$).

Discussion

In the present study, we describe alterations and sex differences in the pituitary TGF β 1 system of transgenic hCG β + mice. Active and total cytokine levels, TGF β 1 biological activity as well as the expression of *Lthp1*, *T β R2*, *Alk5*, *Smad4* and *Smad7* were found decreased in tumoral hCG β + female pituitaries when compared with WT siblings.

On the other hand, we found that male pituitaries presented higher levels of active and total cytokine than females. In accordance, we also found the expression of several other components of the system increased,

including *Lthp1*, *T β R2*, *Alk5*, *Alk1*, *Smad4* and *Smad7*, and TGF β 1 target genes (*Tmepai* and *Klf14*) in male pituitaries when compared to females.

TGF β 1 being an important inhibitory factor of lactotroph function, we postulate that: 1- decreased TGF β 1 activity found in pituitaries from hCG β + females is involved in their development of prolactinomas; 2- the higher expression of TGF β 1 system found in male pituitaries could protect this sex from the prolactinoma development, even in the presence of high levels of hCG.

To demonstrate the involvement of the reduced pituitary TGF β 1 activity in prolactinoma development in hCG β + female mice, we conducted an *in vivo* treatment to recover the pituitary-active TGF β 1 concentration. In fact, we found that ABT-898 treatment was successful in restoring pituitary TGF β 1 activity and, in accordance, pituitary weight, as well as the serum prolactin levels, were reduced in the ABT-treated hCG β + group.

As mentioned before, the hyperstimulation of the immature ovary by constant high hCG levels, induces a marked alteration in ovarian steroid production at early stage of sexual maturation in hCG β + females and induces precocious puberty, and production of high levels of estradiol, testosterone and progesterone during the first month of age. Subsequently, the persistent high hCG levels induces a massive luteinization and a constant increase in serum progesterone. By 6 months of age, females, but not males, present with large prolactinomas and marked hyperprolactinemia (Rulli *et al.* 2002, Ratner *et al.* 2012). Even though the effect of chronically elevated levels of estradiol is well known to induce experimental prolactinomas (Heaney *et al.* 1999, 2002), adult hCG β + females present normal estradiol levels. In a previous work, amplifying effect of progesterone was demonstrated on the growth of these estrogen-dependent tumors in hCG β + females (Ahtiainen *et al.* 2010). However, males exposed to high serum levels of hCG and androgens do not develop pituitary tumors (Ahtiainen *et al.* 2005). Thus, additional factors must be involved in the development of prolactinomas in hCG β + females.

The elevated estrogens level presented by hCG β + females at early age was proposed to partially explain the occurrence of prolactinoma in adulthood (Rulli *et al.* 2002, Ratner *et al.* 2012). In fact, an ovariectomy at 6 weeks of age totally abolished the pituitary gland enlargement and the hyperprolactinemia. Perhaps, this fact could initiate the process of transformation that was later accompanied by the effect of other factors, including high progesterone levels. In this regard, it was described that progesterone not only acts at the pituitary level but

Figure 8

Other members of TGF β family. mRNA transcripts were amplified with specific primers by qPCR and normalized to *CyclophilinB*. Results are expressed relative to those WT females ($n=5-7/\text{group}$) and analyzed by two-way ANOVA. Bonferroni's *post hoc* test was conducted when the interaction between effects was significant. (A) *Tgf β 3* mRNA expression: genotype $\times$ sex interaction ($P=0.9966$). Sex differences: a, $P<0.0009$. No differences among genotypes were found. (B) *Bmp4* mRNA expression. Genotype $\times$ sex interaction: $P=0.0055$. Sex differences: a, $P<0.0001$. Differences among genotypes were found only in females ($*P<0.001$ vs wt female).

also in the hypothalamus, where it suppresses messenger ribonucleic acid levels in the arcuate nucleus (Arbogast & Voogt 1993, 1994).

In fact, the high levels of progesterone present in hCG β + female could be involved in the decreased expression of hypothalamic *Th* we found in this group. Because TH activity is the main critical factor that controls DA synthesis, its decreased activity could influence the DA levels reaching the pituitary. In accordance, the *Drd2* expression was found increased in pituitaries from hCG β + female compared to their WT siblings, and it could be reflecting a lower dopaminergic tone in this group.

As DA, acting through the *Drd2*, upregulates TGF β 1 and *T β R2* expression in lactotrophs (Sarkar *et al.* 2005), as well as the local cytokine activity (Recouvreur *et al.* 2011), the reduced levels of active and total TGF β 1, as well as *T β R2* expression we found in tumoral pituitaries from hCG β + female, could reflect a lower dopaminergic tone in hCG β + females. However, no differences were found in hypothalamic DA concentration, measured by HPLC, among WT and hCG β + females. The pressure exercised on the median eminence by the prolactinoma in hCG β + females could prevent the release and transport of DA and other hypothalamic factors toward the pituitary. Nevertheless, with the present results, we cannot assure that the lower TGF β 1 activity found in hCG β + female pituitaries is a consequence of lower dopaminergic tone reaching the pituitaries in this group, and this deserves future studies.

On the other hand, in males, lower hypothalamic *Th* and higher pituitary *Drd2* expression were observed,

according to lower dopaminergic tone in this sex compared to females (Gudelsky & Porter 1981, Freeman *et al.* 2000), but interestingly, the hCG β overexpression did not induce alterations in males.

The reduced expression of the other components of TGF β 1 system we observed in hCG β + female pituitaries could be related to the decreased TGF β 1 biological activity found in this group. In this regard, it was described that the cytokine enhances its own expression as well as *Ltbp1* levels in several normal and transformed cells (Taipale *et al.* 1996, Weikkolainen *et al.* 2003). Moreover, a dose-related increase in *Ltbp1* production was demonstrated in response to treatment with TGF β 1 (Dallas *et al.* 1994, Koli & Keski-Oja 1995). *Smad7* transcription is also regulated by TGF β 1 through direct binding of Smad3 and Smad4 to the *Smad7* promoter (Nagarajan *et al.* 1999, Stopa *et al.* 2000). On the contrary, we did not observe genotype differences in the pituitary TGF β 1 system in males. Moreover, all the components evaluated were found increased in male pituitaries, compared to WT females, and this factor could protect them from tumor development.

Other members of the TGF β growth factor family, such as TGF β 3 and BMP4, have also been shown to play a role in prolactinoma development. Because *Tgf β 3* is synthesized by lactotrophs, we could expect increased pituitary *Tgf β 3* expression reflecting the increase in the proportion of lactotrophs in hCG β + female pituitaries. However, we did not find significant genotype differences. As pituitary *Tgf β 3* mRNA levels are regulated by estradiol (Hentges *et al.* 2000), the lack of genotype differences could be a consequence of normal and physiological levels of estradiol present in hCG β + females (Rulli *et al.* 2002). On the other hand, the decreased *Tgf β 3* mRNA levels found in male pituitaries could be the result of lower serum estradiol level in this sex. Hence, with this result, we demonstrated that the prolactinoma development in hCG β + females does not depend on pituitary *Tgf β 3* expression.

Regarding pituitary BMP4 expression, it has been previously demonstrated, by immunohistochemistry, that it is principally confined to the somatotroph, corticotroph and thyrotroph cell populations, and rarely detectable in lactotroph cells in normal pituitary (Giacomini *et al.* 2006). However, BMP4 protein was found overexpressed in several experimental models of prolactinomas, and even in human prolactinomas compared with normal pituitaries (Paez-Pereda *et al.* 2003). However, and in contrast to these previous findings, other group found BMP4 overexpression only in a low proportion of the human prolactinoma assayed, finding reduced BMP4 expression in the others (Yacub-Usman *et al.* 2012).

When we assayed *Bmp4* mRNA expression in the hCG β + mouse model, we found it significantly reduced in hCG β + female pituitaries compared with their WT siblings. On the other hand, we found a sharp gender difference. Male pituitaries express greatly reduced levels of *Bmp4* without differences among genotypes. It would therefore be worth finding out the causes and consequences of (a) the gender differences found and (b) the decreased *Bmp4* mRNA expression found in hCG β + female pituitaries. With the present results, we could assure that the prolactinoma development in hCG β + female does not depend on *Bmp4* overexpression.

Gender differences in prolactinoma incidence and behavior have been previously described. Women present higher prevalence of prolactinomas during the fertile period (20–50 years), when the tumor ratio between the sexes is estimated to be 10:1. But after the fifth decade of life, when serum estradiol decreases, this sexual difference disappears and the frequency is similar between sexes. The higher levels of serum estradiol have been proposed to be involved in the higher incidence of prolactinomas in fertile women (Colao *et al.* 2003, Gillam *et al.* 2006).

Interestingly, we have previously demonstrated that estradiol negatively controls most of the components of the TGF β 1 system (Recouvreux *et al.* 2013). In fact, we here described sex differences in the pituitary TGF β 1 system in this model, as we had previously observed in another well-characterized model of prolactinoma, the transgenic knockout mice lacking functional dopamine receptor type 2 (Drd2 $^{-/-}$).

In summary, we postulate that the reduced TGF β 1 activity we found in hCG β + female pituitaries is involved in the development of female prolactinomas. We demonstrated that by enhancing the pituitary TGF β 1 activity, we succeeded in reducing the tumor growth, decreasing the hyperprolactinemia and recovering the inhibition of hormone secretion in hCG β + females.

Even though the high serum progesterone levels could amplify the effect of normal estradiol, acting directly on lactotroph proliferation, it also induced a decrease in hypothalamic TH, and it could decrease the dopamine levels reaching the pituitary. The influence of these factors merits future studies.

On the other hand, the sex differences observed in regulation of the pituitary TGF β 1 system could explain the gender differences found in the incidence of prolactinoma development: the stronger TGF β 1 system found in male pituitaries could protect them from excessive lactotroph proliferation.

Finally, prolactinomas are the most prevalent type of hormone-secreting pituitary tumors in humans, and generally respond well to the therapies with dopamine agonists. However, for patients exhibiting resistance to these drugs, alternative treatments are desired. Our results place the synthetic TSP-1 analogue as potential alternative or complementary therapy in current treatments against prolactinomas, especially in those that are resistant to dopaminergic drugs.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the Agencia Nacional de Promoción Científica y Técnica, Buenos Aires, Argentina (grant PICT N2136 to G D T), CONICET, Argentina (PIP 183 to S B R), René Barón Foundation (Argentina, to G D T and S B R) and Williams Foundation (Argentina, to G D T and S B R).

Acknowledgements

The authors thank the National Institute of Diabetes and Digestive and Kidney Diseases National Hormone and Pituitary Program and Dr A F Parlow for prolactin RIA kit.

References

- Ahtiainen P, Rulli SB, Shariatmadari R, Pelliniemi LJ, Toppari J, Poutanen M & Huhtaniemi IT 2005 Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice. *Oncogene* **24** 7301–7309. (doi:10.1038/sj.onc.1208893)
- Ahtiainen P, Sharp V, Rulli SB, Rivero-Muller A, Mamaeva V, Roytta M & Huhtaniemi I 2010 Enhanced LH action in transgenic female mice expressing hCG β -subunit induces pituitary prolactinomas; the role of high progesterone levels. *Endocrine-Related Cancer* **17** 611–621. (doi:10.1677/ERC-10-0016)
- Arbogast LA & Voogt JL 1993 Progesterone reverses the estradiol-induced decrease in tyrosine hydroxylase mRNA levels in the arcuate nucleus. *Neuroendocrinology* **58** 501–510. (doi:10.1159/000126583)
- Arbogast LA & Voogt JL 1994 Progesterone suppresses tyrosine hydroxylase messenger ribonucleic acid levels in the arcuate nucleus on proestrus. *Endocrinology* **135** 343–350. (doi.org/10.1210/en.135.1.343)
- Ben-Jonathan N 1985 Dopamine: a prolactin inhibiting hormone. *Endocrine Reviews* **6** 564–589. (doi:10.1210/edrv-6-4-564)
- Ben Jonathan N & Hnasko R 2001 Dopamine as a prolactin (PRL) inhibitor. *Endocrine Reviews* **22** 724–763. (doi:10.1210/edrv.22.6.0451)
- Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, *et al.* 2003 PMEP1A1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. *Cancer Research* **63** 1568–1575.

- Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B & Lombardi G 2003 Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. *European Journal of Endocrinology* **148** 325–331. (doi:10.1530/eje.0.1480325)
- Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR & Bonewald LF 1994 Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. *Journal of Biological Chemistry* **269** 6815–6821.
- Freeman ME, Kanyicska B, Lerant A & Nagy G 2000 Prolactin: structure, function, and regulation of secretion. *Physiological Reviews* **80** 1523–1631.
- Galvin-Burgess KE, Travis ED, Pierson KE & Vivian JL 2013 TGF-beta-superfamily signaling regulates embryonic stem cell heterogeneity: self-renewal as a dynamic and regulated equilibrium. *Stem Cells* **31** 48–58. (doi:10.1002/stem.1252)
- Gharib SD, Wierman ME, Shupnik MA & Chin WW 1990 Molecular biology of the pituitary gonadotropins. *Endocrine Reviews* **11** 177–199. (doi:10.1210/edrv-11-1-177)
- Giacomini D, Pérez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M, et al. 2006 Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. *Endocrinology* **147** 247–256. (doi:10.1210/en.2005-0958)
- Gillam MP, Molitch ME, Lombardi G & Colao A 2006 Advances in the treatment of prolactinomas. *Endocrine Reviews* **27** 485–534. (doi:10.1210/en.2005-9998)
- Gudelsky GA & Porter JC 1981 Sex-related difference in the release of dopamine into hypophyseal portal blood. *Endocrinology* **109** 1394–1398. (doi:10.1210/endo-109-5-1394)
- Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, et al. 2005 Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. *Journal of Medicinal Chemistry* **48** 2838–2846. (doi:10.1021/jm0401560)
- Heaney AP, Horwitz GA, Wang Z, Singson R & Melmed S 1999 Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. *Nature Medicine* **5** 1317–1321. (doi:10.1038/15275)
- Heaney AP, Fernando M & Melmed S 2002 Functional role of estrogen in pituitary tumor pathogenesis. *Journal of Clinical Investigation* **109** 277–283. (doi:10.1172/JCI0214264)
- Heldin CH, Landstrom M & Moustakas A 2009 Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. *Current Opinion in Cell Biology* **21** 166–176. (doi:10.1016/j.ceb.2009.01.021)
- Hentges S, Pastorcic M, De A, Boyadjieva N & Sarkar DK 2000 Opposing actions of two transforming growth factor-beta isoforms on pituitary lactotropic cell proliferation. *Endocrinology* **141** 1528–1535. (doi:10.1210/en.141.4.1528)
- Itoh F, Watabe T & Miyazono K 2014 Roles of TGF-beta family signals in the fate determination of pluripotent stem cells. *Seminars in Cell and Developmental Biology* **32** 98–106. (doi:10.1016/j.semcdb.2014.05.017)
- Jonas KC, Oduwole OO, Peltoketo H, Rulli SB & Huhtaniemi IT 2014 Mouse models of altered gonadotrophin action: insight into male reproductive disorders. *Reproduction* **148** R63–R70. (doi:10.1530/REP-14-0302)
- Koli K & Keski-Oja J 1995 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. *Cancer Research* **55** 1540–1546.
- Lawler J 2002 Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. *Journal of Cellular and Molecular Medicine* **6** 1–12. (doi:10.1111/j.1582-4934.2002.tb00307.x)
- Levy L & Hill CS 2005 Smad4 dependency defines two classes of transforming growth factor β (TGF- β) target genes and distinguishes TGF- β -induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. *Molecular and Cellular Biology* **25** 8108–8125. (doi:10.1128/MCB.25.18.8108-8125.2005)
- Maurer RA 1982 Estradiol regulates the transcription of the prolactin gene. *Journal of Biological Chemistry* **257** 2133–2136.
- Missale C, Nash SR, Robinson SW, Jaber M & Caron MG 1998 Dopamine receptors: from structure to function. *Physiological Reviews* **78** 189–225.
- Nagarajan RP, Zhang J, Li W & Chen Y 1999 Regulation of Smad7 promoter by direct association with Smad3 and Smad4. *Journal of Biological Chemistry* **274** 33412–33418. (doi:10.1074/jbc.274.47.33412)
- Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST, et al. 2003 Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. *PNAS* **100** 1034–1039. (doi:10.1073/pnas.0237312100)
- Pastorcic M, De A, Boyadjieva N, Vale W & Sarkar DK 1995 Reduction in the expression and action of transforming growth factor-b1 on lactotropes during estrogen-induced tumorigenesis. *Cancer Research* **55** 4892–4898.
- Ratner LD, Gonzalez B, Ahtiainen P, Di Giorgio NP, Poutanen M, Calandra RS, Huhtaniemi IT & Rulli SB 2012 Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility. *Endocrinology* **153** 5980–5992. (doi:10.1210/en.2012-1393)
- Recouvreux MV, Guida MC, Rifkin DB, Becu-Villalobos D & Diaz-Torga G 2011 Active and total transforming growth factor- β 1 are differentially regulated by dopamine and estradiol in the pituitary. *Endocrinology* **152** 2722–2730. (doi:10.1210/en.2010-1464)
- Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D & Diaz-Torga G 2012 Thrombospondin-1 (TSP-1) Analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-beta1 (TGF-beta1). *Endocrinology* **153** 3861–3871. (doi:10.1210/en.2012-1007)
- Recouvreux MV, Lapyckyj L, Camilletti MA, Guida MC, Ornstein A, Rifkin DB, Becu-Villalobos D & Diaz-Torga G 2013 Sex differences in the pituitary transforming growth factor-beta1 system: studies in a model of resistant prolactinomas. *Endocrinology* **154** 4192–4205. (doi:10.1210/en.2013-1433)
- Recouvreux MV, Camilletti MA, Rifkin DB & Diaz-Torga G 2016 The pituitary TGFbeta1 system as a novel target for the treatment of resistant prolactinomas. *Journal of Endocrinology* **228** R73–R83. (doi:10.1530/JOE-15-0451)
- Rulli SB, Kuorelahti A, Karaer O, Pelliniemi LJ, Poutanen M & Huhtaniemi I 2002 Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. *Endocrinology* **143** 4084–4095. (doi:10.1210/en.2002-220490)
- Rulli SB, Zitta K, Calandra RS & Campo S 2003 Effect of dihydrotestosterone on pituitary follicle-stimulating hormone isoforms in adult male rats treated with a gonadotropin-releasing hormone antagonist. *Neuroendocrinology* **78** 280–286. (doi:10.1159/000074449)
- Sarkar DK, Kim KK & Minami S 1992 Transforming growth factor-beta1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. *Molecular Endocrinology* **6** 1825–1833. (doi:10.1210/me.6.11.1825)
- Sarkar DK, Pastorcic M, De A, Engel M, Moses H & Ghasemzadeh MB 1998 Role of transforming growth factor-b type I and TGF-b type II receptors in the TGF-b1 regulated gene expression in pituitary prolactin-secreting lactotropes. *Endocrinology* **139** 3620–3628. (doi:10.1210/endo.139.8.6135)
- Sarkar DK, Chaturvedi K, Oomizu S, Boyadjieva NI & Chen CP 2005 Dopamine, dopamine D2 receptor short isoform, transforming

- growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes. *Endocrinology* **146** 4179–4188. (doi:10.1210/en.2005-0430)
- Stopa M, Anhuif D, Terstegen L, Gatsios P, Gressner AM & Dooley S 2000 Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. *Journal of Biological Chemistry* **275** 29308–29317. (doi:10.1074/jbc.M003282200)
- Taipale J, Saharinen J, Hedman K & Keski-Oja J 1996 Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. *Journal of Histochemistry and Cytochemistry* **44** 875–889. (doi:10.1177/44.8.8756760)
- Truty MJ, Lomberk G, Fernandez-Zapico ME & Urrutia R 2009 Silencing of the transforming growth factor-beta (TGFBeta) receptor II by Kruppel-like factor 14 underscores the importance of a negative feedback mechanism in TGFBeta signaling. *Journal of Biological Chemistry* **284** 6291–6300. (doi:10.1074/jbc.M807791200)
- Weikkolainen K, Keski-Oja J & Koli K 2003 Expression of latent TGF-beta binding protein LTBP-1 is hormonally regulated in normal and transformed human lung fibroblasts. *Growth Factors* **21** 51–60. (doi:10.1080/08977198310001598778)
- Yacqub-Usman K, Duong CV, Clayton RN & Farrell WE 2012 Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a potential target for epidrug-induced re-expression. *Endocrinology* **153** 3603–3612. (doi:10.1210/en.2012-1231)

Received in final form 2 December 2016

Accepted 17 January 2017

Accepted Preprint published online 17 January 2017